4168.TWO GlycoNex

Healthcare Biotechnology Taiwan OTC Exchange
19.95 TWD
Close of Nov 6, 2026
18.30 30.00
Market cap
TWD 2.24B
P/E
-
P/B
2.68x
ROE
-30.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4168.TWO undervalued?

Graham number

The Graham number of GlycoNex cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GlycoNex fundamental analysis

No fundamental analysis for GlycoNex yet.

GlycoNex stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GlycoNex

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various …

Full company profile